GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (OTCPK:ATTBF) » Definitions » 1-Year ROIIC %

Abattis Bioceuticals (Abattis Bioceuticals) 1-Year ROIIC % : 0.00% (As of Sep. 2019)


View and export this data going back to . Start your Free Trial

What is Abattis Bioceuticals 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Abattis Bioceuticals's 1-Year ROIIC % for the quarter that ended in Sep. 2019 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Abattis Bioceuticals's 1-Year ROIIC % or its related term are showing as below:

ATTBF's 1-Year ROIIC % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.29
* Ranked among companies with meaningful 1-Year ROIIC % only.

Abattis Bioceuticals 1-Year ROIIC % Historical Data

The historical data trend for Abattis Bioceuticals's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abattis Bioceuticals 1-Year ROIIC % Chart

Abattis Bioceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abattis Bioceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abattis Bioceuticals's 1-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Abattis Bioceuticals's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abattis Bioceuticals's 1-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abattis Bioceuticals's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Abattis Bioceuticals's 1-Year ROIIC % falls into.



Abattis Bioceuticals 1-Year ROIIC % Calculation

Abattis Bioceuticals's 1-Year ROIIC % for the quarter that ended in Sep. 2019 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -3.032 (Sep. 2019) - -12.146 (Sep. 2018) )/( 12.918 (Sep. 2019) - 1.535 (Sep. 2018) )
=9.114/11.383
=80.07%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Abattis Bioceuticals  (OTCPK:ATTBF) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Abattis Bioceuticals 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abattis Bioceuticals (Abattis Bioceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6
Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.

Abattis Bioceuticals (Abattis Bioceuticals) Headlines

From GuruFocus

Abattis Announces Share Buy Back Program

By Marketwired Marketwired 08-07-2018

Abattis Provides Marketing and Operational Updates

By Marketwired Marketwired 12-21-2018

Abattis Provides Update on Conference Call

By Marketwired Marketwired 02-28-2019

Abattis Strengthens Management Team and Provides Company Updates

By Marketwired Marketwired 09-11-2018

Abattis Completes Sale of Northern Vine Interest

By Marketwired Marketwired 08-14-2018

Abattis Bioceuticals Provides Update on Vaporizer Product Line

By Marketwired Marketwired 10-12-2018